Diabetic Macular Edema

Retina experts discuss the benefits of using intraocular steroids to treat patients with DME as well as their approach to switching to steroids after a poor response to anti-VEGF therapy.

Expert retina specialists provide an overview of the YOSEMITE and RHINE clinical studies of faricimab in the treatment of DME.

Ala Moshiri, MD, PhD, provides an overview of current treatment options for diabetic macular edema.

Investigators have enrolled the 112 patients in the KALAHARI phase 2, part B clinical trial for diabetic macular edema (DME). This is above the originally planned total of 108 patients.

Senescent cells accumulate in areas of disease activity in DME and wet age-related macular degeneration and release mediators that drive the pathology. UBX1325 seems to prevent that disease activity.

Patients who are non-responders to anti-vascular endothelial growth factor (VEGF) therapy may benefit from intravitreal dexamethasone.

Carl Regillo, MD, FACS, FASRS, and Prethy Rao, MD, MPH, discuss the phase 3 trials of faricimab in the treatment of DME and highlighting the enhanced resolution of intraocular fluid.

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, review the challenges presented in the management of DME, including the disease burden on the patient.

Retina experts discuss biomarkers to track disease progression in neovascular AMD, as well as their thoughts on the utility of optical coherence tomography angiography (OCT-A).

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their approaches to dosing recommendations for faricimab in the treatment of neovascular AMD.

Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.

Oxurion NV has reached its enrollment target of 108 patients in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) and will likely continue to include additional participants in the trial due to high interest.

Alimera Sciences, Inc. has completed enrollment for its NEW DAY clinical trial (NCT04469595). Participants are patients diagnosed with diabetic macular edema (DME).

Expert retina specialists review the safety profile of faricimab compared with other anti-VEGF therapies in AMD.

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, discuss patient selection for faricimab in neovascular AMD, as well as approaches to switching to faricimab after a poor response to other treatment.

Allgenesis announces preliminary data for its on-going trial and anticipates the release of the final topline data in 4Q23.

DIAMOND is a Phase 3, two-stage, double-masked, randomized, multi-center trial to assess the efficacy and safety of OCS-01 eye drops in DME patients. The primary objective of Stage 1 was to select the optimal dosing regimen.

Expert retina specialists discuss the use of faricimab and dosing for the treatment of neovascular age-related macular degeneration in the clinical practice setting.

Drs Nathan Steinle, Adrienne Scott, and Carl Regillo comment on the phase 3 trial outcomes of faricimab in neovascular AMD.

Retina experts discuss treatment of wet AMD, focusing on frequency of treatment and treatment breaks, and fluid tolerance.

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, provide an overview of the effect of anti-VEGF treatment in neovascular age-related macular degeneration and diabetic macular edema.

D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Genentech announced post-hoc data indicating treatment with faricimab-svoa (Vabysmo) led to greater and faster drying of retinal fluid with fewer injections for the treatments of wet AMD and DME, when compared to aflibercept.

A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks.

According to the companies,Horus will increase Iluvien’s commercial presence with Nordic retinal specialists.